Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 439

1.

Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.

Meyer-Wyss B, Rich P, Egger H, Helbling B, Müllhaupt B, Rammert C, Gonvers JJ, Oneta C, Criblez D, Rossi L, Borovicka J, Meyenberger C, Arn M, Renner EL; Swiss Association for the Study of the Liver (SASL)..

J Viral Hepat. 2006 Jul;13(7):457-65.

PMID:
16792539
2.

Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin.

Oze T, Hiramatsu N, Yakushijin T, Kurokawa M, Igura T, Mochizuki K, Imanaka K, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Tamura S, Yoshihara H, Hayashi E, Inoue A, Imai Y, Kato M, Yoshida Y, Tatsumi T, Ohkawa K, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N.

J Viral Hepat. 2009 Aug;16(8):578-85. doi: 10.1111/j.1365-2893.2009.01116.x. Epub 2009 Jun 22.

PMID:
19552663
3.

Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.

Abergel A, Hezode C, Leroy V, Barange K, Bronowicki JP, Tran A, Alric L, Castera L, Bernard PH, Henquell C, Lafeuille H, Ughetto S, Darcha C, Chevallier M, Martineau N, Dubost S, Randl K, Dhumeaux D, Bommelaer G, Bonny C; French multicenter study group..

J Viral Hepat. 2006 Dec;13(12):811-20.

PMID:
17109680
4.

Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.

Sood A, Midha V, Hissar S, Kumar M, Suneetha PV, Bansal M, Sood N, Sakhuja P, Sarin SK.

J Gastroenterol Hepatol. 2008 Feb;23(2):203-7. Epub 2007 Jul 20.

PMID:
17645472
5.
6.

Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study.

Brady DE, Torres DM, An JW, Ward JA, Lawitz E, Harrison SA.

Clin Gastroenterol Hepatol. 2010 Jan;8(1):66-71.e1. doi: 10.1016/j.cgh.2009.08.036. Epub 2009 Sep 10.

PMID:
19747986
7.

Dose comparison study of pegylated interferon-alpha-2b plus ribavirin in naïve Japanese patients with hepatitis C virus genotype 2: a randomized clinical trial.

Kawaoka T, Kawakami Y, Tsuji K, Ito H, Kitamoto M, Aimitsu S, Kawakami H, Jeong SC, Imamura M, Aikata H, Takahashi S, Chayama K.

J Gastroenterol Hepatol. 2009 Mar;24(3):366-71. doi: 10.1111/j.1440-1746.2008.05650.x. Epub 2008 Nov 20.

PMID:
19032459
8.

A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group.

Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S, Clement RP.

Hepatology. 2000 Sep;32(3):647-53.

PMID:
10960463
9.
10.

Weekly pegylated interferon alpha-2b vs daily interferon a-2b versus standard regimen of interferon a-2b in the treatment of patients with chronic hepatitis C virus infection.

Horsmans Y, Colle I, Van Vlierberghe H, Langlet P, Adler M, Bourgeois N, Brenard R, Michielsen P, Goossens A, Bruckers L; Belgian Assocation for the Study of the Liver..

Acta Gastroenterol Belg. 2008 Jul-Sep;71(3):293-7.

PMID:
19198574
11.

Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C.

Younossi ZM, McCullough AC, Barnes DS, Post A, Ong JP, O'Shea R, Martin LM, Bringman D, Farmer D, Levinthal G, Mullen KD, Carey WD, Tavill AS, Ferguson R, Gramlich T.

Dig Dis Sci. 2005 May;50(5):970-5.

PMID:
15906777
13.

Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C.

Zeuzem S, Yoshida EM, Benhamou Y, Pianko S, Bain VG, Shouval D, Flisiak R, Rehak V, Grigorescu M, Kaita K, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG.

Hepatology. 2008 Aug;48(2):407-17. doi: 10.1002/hep.22403.

PMID:
18666223
14.

Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.

Myers RP, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T.

AIDS. 2004 Jan 2;18(1):75-9.

PMID:
15090832
15.

Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.

Lee SD, Yu ML, Cheng PN, Lai MY, Chao YC, Hwang SJ, Chang WY, Chang TT, Hsieh TY, Liu CJ, Chen DS.

J Viral Hepat. 2005 May;12(3):283-91.

PMID:
15850469
16.

Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.

de Lédinghen V, Trimoulet P, Winnock M, Foucher J, Bourlière M, Desmorat H, Canva V, Capron D, Lévy S, Mion F, Mannant PR, Chêne G, Fleury H, Couzigou P, Bernard PH; French Multicenter Study Group..

J Hepatol. 2002 May;36(5):672-80.

PMID:
11983451
17.

Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.

Buti M, Sanchez-Avila F, Lurie Y, Stalgis C, Valdés A, Martell M, Esteban R.

Hepatology. 2002 Apr;35(4):930-6.

PMID:
11915041
18.

Efficacy of low dose peginterferon alpha-2b with ribavirin on chronic hepatitis C.

Gupta R, Ramakrishna CH, Lakhtakia S, Tandan M, Banerjee R, Reddy DN.

World J Gastroenterol. 2006 Sep 14;12(34):5554-6.

19.

A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C.

You BC, Kim YS, Kim Hi, Kim SH, Park SS, Seo YR, Kim SG, Lee SW, Kim HS, Jeong SW, Jang JY, Kim BS.

Clin Mol Hepatol. 2012 Sep;18(3):272-8. doi: 10.3350/cmh.2012.18.3.272. Epub 2012 Sep 25.

20.

Supplemental Content

Support Center